View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
June 26, 2020

Gilead’s remdesivir to commence Phase I trials as inhaled therapy to target mild Covid-19 patients

By Victoria Smith

Earlier this month, Gilead announced that it will commence Phase I clinical trials for inhaled remdesivir in healthy volunteers, with the aim to extend further studies in patients with Covid-19 in the following months. This follows previous studies highlighting that intravenously administered remdesivir did not provide a meaningful benefit to milder Covid-19 patients. Despite this, an inhaled formulation might work in a different manner.

GlobalData forecasts that the inhaled formulation will target this population, administered by way of a nebuliser for patients to self-administer away from hospitals so staff can prioritise beds for more critical patients. Read more here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena